Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing peptide drug therapies targeting areas of unmet need across rare and prevalent diseases.

Protagonist Therapeutics Inc.

Domain Not Resolving

reCAPTCHA v2

Cloudflare Bot Manager

Google Remarketing

MediaElement.js

ASP.NET Ajax

Hubspot

Hubspot Forms

Cloudflare SSL

Google Analytics IP Anonymization

Director, President & CEO

Dinesh Patel

President & CEO

Chief Financial Officer

Don Kalkofen

Executive Vice President, Chief Drug Discovery and Preclinical Development Officer

Ashok Bhandari

Healthcare

Betsy Lindemulder

Executive Director, Global Regulatory Affairs

Brandon Porter

Business Management

Catarina Tran

Director, Medicinal Chemistry

Chengguo Dong

Senior Director Supply Chain

Hanh-Uyen Nguyen

Director

Harlan Reese

William D. Waddill

Sarah O'Dowd

Mark Smythe

Founder and Vice President of Technology & Alliances

David Y. Liu

Chief Scientific Officer

Matthew Gosling

Executive Vice President, General Counsel

Tom O'Neil

Asif Ali

Executive Vice President and Chief Financial Officer

Newman Yeilding

Health Care Public Companies

Health Care Companies With More Than $50M in Revenue (Top 10K)

Asia-Pacific (APAC) Companies With Fewer Than 100 Employees (Top 10K)

GlaxoSmithKline Alumni Founded Companies

Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Post-IPO Equity - Protagonist Therapeutics

MidCap Financial

Silicon Valley Bank

Post-IPO Debt - Protagonist Therapeutics

National Institutes of Health

Grant - Protagonist Therapeutics

Canaan Partners

Series C - Protagonist Therapeutics

Pharmstandard

Series B - Protagonist Therapeutics

Johnson & Johnson Development Corporation

Series A - Protagonist Therapeutics

Brisbane

Queensland

Australia

Oceania

Protagonist Therapeutics

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Protagonist takes center stage with Phase III fillip

Protagonist, J&J’s oral IL-23 psoriasis data strong (but short)

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Protagonist Therapeutics Director Sells 8,000 Shares

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care

United States

North America

Germany

Europe

India

Asia

Taiwan

HTML5

Wordpress

GlobalSign

F5 NGINX

GreenSock Animation Platform

Bootstrap

Vimeo

Apache Server

Google Analytics

Google Maps API

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 5:38 AM	b1fd8482
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 5:38 AM	63f3facb
crunchbase trigger	general	Nov 25, 2024 9:06 AM	5d5d9ac9
crunchbase profile	general	Nov 25, 2024 10:37 AM	724e14b1
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 4:21 PM	0c755455
peers	general	Oct 16, 2024 5:38 AM	1eddc4ae
news basic	general	Oct 16, 2024 5:38 AM	7c5453d7
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PROTAGONIST-INC

Protagonist Therapeutics Inc.

Last Close

41.65

22/11 21:00

Market Cap

2.04B

Beta: -

Volume Today

1.32M

Avg: -